Lipocine Inc. — fact timeline

Michael Grissinger was appointed as director at Lipocine Inc..

“On August 3, 2026, the Board of Directors of the Company expanded the Board of Directors to five members and appointed Michael Grissinger as a director, effective immediately.”

Lipocine Inc. reported First Quarter Ended March 31, 2026 results: net income net loss of $3.7 million, EPS ($0.52) per diluted share.

“Lipocine reported a net loss of $3.7 million, or ($0.52) per diluted share, for the quarter ended March 31, 2026, compared with a net loss of $1.9 million, or ($0.35) per diluted share, for the quarter ended March 31, 2025.”

Lipocine Inc. reported the full year ended December 31, 2025 results: revenue $2.0 million, net income net loss of $9.6 million, EPS ($1.69) per diluted share.

“per diluted share, for the year ended December 31, 2025, compared with net income of $8,352, or ($0.00) per diluted share, for the year ended December 31, 2024. Revenues were $2.0 million during the year ended December 31, 2025, compared to revenue of $11.2 million during the year ended December 31, 2024. Revenue in 2025 primarily consisted of license revenue from”

Lipocine Inc.: Reduction of authorized common stock from 200,000,000 to 75,000,000 shares via amendment to Amended and Restated Certificate of Incorporation (effective 2025-06-04).

“On June 4, 2025, the Company filed the Amendment with the Secretary of State of the State of Delaware.”

Lipocine Inc.: Filed Certificate of Amendment to Certificate of Designation of Series A Junior Participating Preferred Stock to reflect reverse stock split (effective 2024-10-22).

“On October 22, 2024, in connection with the adoption of the Third Amended and Restated Stockholder Rights Agreement, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Certificate of Designation of the Series A Junior Participating Preferred Stock (the “Certificate of Amendment”) to reflect the impact of the Company’s reverse stock split effected on May 11, 2023.”

Lipocine Inc. terminated Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. valued at terminated effective immediately upon notice; waiver of notice period (effective 2024-04-24).

“On April 24, 2024, the Company provided notice to Cantor Fitzgerald & Co. (“Cantor”) of its election to terminate the Controlled Equity Offering SM Sales Agreement between them dated March 6, 2017 (the “Sales Agreement”).”

Lipocine Inc. entered into ATM Agreement with A.G.P./Alliance Global Partners valued at up to $10,616,169 of Shares; 3.0% of aggregate gross proceeds per sale (effective 2024-04-26).

“On April 26, 2024, Lipocine Inc. (the “Company”), entered into a sales agreement (the “ATM Agreement”) with A.G.P./Alliance Global Partners (“A.G.P.”), as sales agent, pursuant to which the Company may offer and sell shares of common stock, par value $0.0001 per share (the “Shares”), from time to time, in an at-the-market public offering.”

Lipocine Inc. reported the year ended December 31, 2023 results: revenue $2.9 million, net income net loss of $16.4 million, EPS ($3.14) per diluted share.

“per diluted share, for the year ended December 31, 2022. During 2023 Lipocine recognized a non-cash minimum guaranteed royalties reversal of variable consideration revenue of $2.9 million related to the termination of the Antares License Agreement. The reversal of revenue is due to the fact that, as a result of the termination of the license agreement, the Company”

Lipocine Inc. entered into License Agreement with Gordon Silver Limited and Verity Pharmaceuticals, Inc. valued at $11 million license fee (effective 2024-01-12).

“On January 12, 2024, Lipocine Inc. (the “Company”) entered into a License Agreement (the “License Agreement”) with Gordon Silver Limited (“GSL”) and Verity Pharmaceuticals, Inc. (“Verity Pharma”)”

Lipocine Inc.: Stockholders approved and Board set a reverse stock split ratio of 1-for-17, amending the Certificate of Incorporation (effective 2023-05-11).

“the Company’s stockholders approved an amendment (the “Amendment”) to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split at a ratio not less than 1-for-5 and not greater than 1-for-20, with the exact ratio to be set within that range at the discretion of our Board of Directors without further approval or authorization from our stockholders. On May 10, 2023, the Company’s Board of Directors approved a reverse stock split ratio of 1-for-17. The Company filed the Amendment with the Secretary of State of the State of Delaware on May 10, 2023, which will be effective at 5:00 p.m. Eastern Time on Thursday, May 11, 2023.”

Lipocine Inc. shareholders approved Adjournment of the Annual Meeting, if necessary, to continue to solicit votes in favor of the foregoing proposals. at the 2023-05-10 meeting.

“(5) Adjournment of the Annual Meeting, if necessary, to continue to solicit votes in favor of the foregoing proposals. The following table sets forth the vote of the shareholders at the meeting with respect adjournment of the Annual Meeting, if necessary: For Against Abstain Broker Non-Vote 49,009,647,687 9,255,800,253 443,789,647 0”

Lipocine Inc. shareholders approved Amendment to the Certificate of Incorporation to effect a reverse stock split at a ratio not less than 1-for-5 and not greater than 1-for-20, with the exact ratio to be set within that range at the discretion of our Board of Directors without further approval or authorization of our stockholders. at the 2023-05-10 meeting.

“(4) Amendment to the Certificate of Incorporation to effect a reverse stock split at a ratio not less than 1-for-5 and not greater than 1-for-20, with the exact ratio to be set within that range at the discretion of our Board of Directors without further approval or authorization of our stockholders. The following table sets forth the vote of the shareholders at the meeting with respect to this proposal: For Against Abstain 50,686,571,936 7,647,924,984 374,740,667”

Lipocine Inc. shareholders approved Advisory Vote on Executive Compensation at the 2023-05-10 meeting.

“(3) Advisory Vote on Executive Compensation. The Company’s shareholders voted upon and adopted a non-binding resolution approving the compensation of the Company’s named executive officers. The following table sets forth the vote of the shareholders at the meeting with respect to the adoption of this resolution on named executive officer compensation: For Against Abstain Broker Non-Vote 24,072,367 6,881,264 4,120,949 23,576,007”

Lipocine Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-05-10 meeting.

“(2) Ratification of Appointment of Independent Registered Public Accounting Firm. The Company’s shareholders voted upon and ratified the appointment of Tanner LLC as the Company’s independent registered public accountants for the fiscal year ending December 31, 2023. The following table sets forth the vote of the shareholders at the meeting with respect to the appointment of Tanner LLC: For Against Abstain 56,323,599 1,736,236 590,752 There were no broker non-votes in the ratification of appointment of Tanner LLC as the Company’s independent registered public accountants for the fiscal year ending December 31, 2023.”

Lipocine Inc. shareholders approved Election of Directors at the 2023-05-10 meeting.

“(1) Election of Directors. The Company’s shareholders elected for a one-year term six persons nominated for election as directors. The following table sets forth the vote of the shareholders at the meeting with respect to the election of directors: Nominee For Withheld Broker Non-Vote Dr. Mahesh V. Patel 29,582,605 5,491,975 23,576,007 Jeffrey A. Fink 29,801,182 5,273,398 23,576,007 John W. Higuchi 29,628,218 5,446,362 23,576,007 Dr. Jill M. Jene 30,238,299 4,836,281 23,576,007 Dr. Richard Dana Ono 30,083,770 4,990,810 23,576,007 Dr. Spyros Papapetropoulos 30,630,129 4,444,451 23,576,007 There were no abstentions with respect to the election of directors.”

Lipocine Inc.: Bylaw amendment to reduce the stockholder quorum requirement from a majority to one-third of outstanding shares entitled to vote (effective 2023-03-07).

“On March 7, 2023, the board of directors the (“ Board ”) of Lipocine Inc. (the “ Company ”), adopted and approved an amendment to the Company’s Amended and Restated Bylaws (the “ Bylaws Amendment ”) in order to change the number of stockholders required to constitute a quorum at a meeting of stockholders, from requiring a majority, to requiring one-third, of the outstanding shares of stock entitled to vote, present in person, by remote communication, or represented by proxy.”

Lipocine Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“December 6, 2022, the Company received notification from Nasdaq indicating that the Company will have an additional 180-day grace period, until June 5, 2023, to regain compliance with the Nasdaq Marketplace Rule’s $1.00 minimum bid requirement. The notification indicated that the Company did not regain compliance during the initial 180-day grace period provided under the rule. In accordance with Nasdaq Marketplace Rule 5810(c)(3)(A), the Company is eligible for the additional grace period because it meets the continued listing requirement for market value of publicly held shares and all other”

Spyros Papapetropoulos was appointed as Director at Lipocine Inc..

“On April 11, 2022, the Board of Directors of the Company expanded the Board of Directors to six members and appointed Dr. Jill M. Jene and Dr. Spyros Papapetropoulos as directors, effective immediately.”

Jill M. Jene was appointed as Director at Lipocine Inc..

“On April 11, 2022, the Board of Directors of the Company expanded the Board of Directors to six members and appointed Dr. Jill M. Jene and Dr. Spyros Papapetropoulos as directors, effective immediately.”

Krista Fogarty was appointed as Principal Accounting Officer at Lipocine Inc..

“As previously disclosed, on January 19, 2022, the Board of Directors of the Company appointed Krista Fogarty, the Company’s Corporate Controller, to also serve as the Principal Accounting Officer of the Company.”

Krista Fogarty was appointed as Principal Accounting Officer at Lipocine Inc..

“On January 19, 2022, the Board of Directors of the Company appointed Krista Fogarty, the Company’s Corporate Controller, to also serve as the Principal Accounting Officer of the Company.”

Mahesh Patel changed role as Principal Financial Officer at Lipocine Inc..

“Upon the effective date of Mr. Brown’s resignation, Mahesh Patel, the Company’s President and Chief Executive Officer, will serve as the Company’s Principal Financial Officer on an interim basis until Mr. Brown’s successor is appointed.”

Morgan Brown resigned as Executive Vice President and Chief Financial Officer at Lipocine Inc..

“On January 17, 2022, Morgan Brown provided Lipocine, Inc. (the “Company”) with notice of his intent to resign from his position as Executive Vice President and Chief Financial Officer of the Company, effective as of January 31, 2022.”